BioOrbit £9.8M Seed Round 2026: Record Raise for In-Space Drug

LONDON, April 30, 2026 — BioOrbit, a London-headquartered startup specialising in pharmaceutical manufacturing aboard low-Earth orbit platforms, has closed a £9.8 million seed round co-led by LocalGlobe and Breega, with participation from Auxxo, Seedcamp, Type One, 7percent, and a group of angel investors. The company claims this is the largest seed round ever raised for in-space manufacturing — a figure that has not yet been independently verified but, if accurate, marks a significant milestone for a sector that has struggled to attract institutional capital at pre-revenue stages. Founded in 2023 by Dr Katie King, who holds a PhD in Nanomedicine from Cambridge and interned at NASA, and Dr Leonor Teles, an oncology researcher, BioOrbit is developing BOX — a compact, autonomous crystallisation unit designed to produce pharmaceutical-grade drug crystals in microgravity. This analysis examines the capital strategy behind the raise, the competitive landscape facing BioOrbit including US rival Varda Space Industries, the regulatory pathway the company is forging with the MHRA, and the broader implications for the projected $1 trillion antibody drug market.

Executive Summary

• BioOrbit raised £9.8 million in a seed round announced on 30 April 2026, co-led by LocalGlobe and Breega.
• The round included participation from Auxxo, Seedcamp, Type One, 7percent, and undisclosed angels.
• BioOrbit claims this is the largest seed raise ever recorded for in-space manufacturing.
• The company's core product, BOX, is a microwave-sized, modular, autonomous manufacturing unit for low-Earth orbit crystallisation.
• The UK Space Agency has funded a £250,000 feasibility study for the system.
• BioOrbit is working with the MHRA and the Regulatory Innovation Office on the first pharmaceutical regulatory pathway for in-orbit manufacturing.
• The antibody drug market is projected to reach $1 trillion, providing a substantial addressable market for reformulated therapies.

Key Developments

The Record Seed Round and Its Backers

The £9.8 million seed round is notable not merely for its size but for the calibre of investors involved. LocalGlobe, the London-based venture capital firm that has backed companies including Wise and Improbable, co-led alongside Paris-headquartered Breega, which focuses on European deep-tech and sustainability ventures. Seedcamp, one of Europe's most prolific early-stage investors, also participated. The angel cohort has not been disclosed by name. Julia Hawkins, General Partner at Phoenix Court / LocalGlobe, framed the investment in terms of healthcare infrastructure rather than space exploration: "BioOrbit turns space into pharmaceutical infrastructure — using microgravity to create drug formulations not possible on Earth and shifting cancer treatment from hospital to home." — Julia Hawkins, General Partner, Phoenix Court / LocalGlobe, TechFundingNews, April 2026. That language — "pharmaceutical infrastructure" — is deliberate. It positions BioOrbit as a biotech play, not a space curiosity, and is designed to attract follow-on capital from healthcare-focused funds rather than space-specialist vehicles alone.

BOX: The Core Technology

BioOrbit's product is called BOX — a compact, modular, autonomous manufacturing unit roughly the size of a domestic microwave oven. The system is designed to operate in low-Earth orbit, where microgravity conditions enable the formation of more uniform protein crystals than those achievable in terrestrial laboratories. Multiple BOX units can be deployed simultaneously, meaning production capacity scales linearly with the number of units in orbit. Dr Katie King, BioOrbit's co-founder and CEO, described the opportunity in crystallographic terms: "We are enabling the creation of more perfect crystals in orbit that unlock drug formulations simply not achievable on Earth — a paradigm shift for cancer therapies and the pharmaceutical industry at large." — Dr Katie King, Founder and CEO, BioOrbit, TechFundingNews, April 2026. The UK Space Agency has already committed £250,000 to a feasibility study for the BOX system, providing early government validation. BioOrbit is also engaged with the MHRA and the Regulatory Innovation Office on developing a first-of-its-kind regulatory pathway for pharmaceuticals manufactured off-planet — a process that, if successful, would establish a precedent with global implications for the European Medicines Agency and the US FDA.

Market Context & Competitive Landscape

Varda Space Industries: The US Front-Runner

BioOrbit operates in a nascent but increasingly contested market. Varda Space Industries, the most heavily funded US competitor, has already returned drug crystals from orbit and is reportedly working toward its first commercial pharmaceutical manufacturing mission. Varda has raised significantly more capital than BioOrbit to date and benefits from closer proximity to both NASA infrastructure and the US pharmaceutical market, the world's largest. Any honest assessment of BioOrbit's position must acknowledge that Varda holds a meaningful operational lead. However, BioOrbit's focus on a repeatable, industrial crystallisation process — as distinct from one-off experimental missions — may offer differentiation if the technology performs as described.

Space Forge and the UK Ecosystem

Space Forge, a Welsh startup, represents the closest UK-based comparison, though its focus on semiconductor and advanced materials manufacturing in space means it does not compete directly with BioOrbit on pharmaceutical applications. The coexistence of both companies within the UK space-manufacturing ecosystem is, however, notable: it suggests that British deep-tech investors and government agencies view in-orbit manufacturing as a credible industrial category rather than a speculative fringe.

Source: TechFundingNews (April 2026); company websites; Business20Channel.tv analysis. *Exact funding totals not confirmed in source; marked as estimates.

Industry Implications

Healthcare: From Hospital Infusion to Home Administration

The core commercial thesis behind BioOrbit rests on a specific clinical bottleneck. Many cancer immunotherapies — particularly monoclonal antibody treatments — must be administered via hospital infusion because the drug crystals produced on Earth are too large or too irregular for subcutaneous injection formulations. If microgravity crystallisation can produce smaller, more uniform crystals, these drugs could potentially be reformulated for self-administration at home. The implications for healthcare systems are substantial. The NHS and comparable public health systems face growing capacity constraints in oncology. Shifting even a fraction of infusion-dependent treatments to home-based subcutaneous delivery would reduce hospital bed occupancy, lower per-treatment costs, and improve patient quality of life. The antibody drug market, projected to reach $1 trillion according to BioOrbit's investor materials, provides the addressable market context.

Regulatory and Policy Dimensions

BioOrbit's engagement with the MHRA and the Regulatory Innovation Office on an in-orbit pharmaceutical manufacturing pathway is arguably as significant as the funding itself. No regulatory framework currently exists anywhere in the world for approving drugs manufactured in space. If the UK establishes this framework first, it could attract other space-pharma companies to register and manufacture under British jurisdiction — a meaningful advantage for the UK's post-Brexit science and industrial strategy. Lord David Willetts, Chair of the UK Space Agency, explicitly tied the opportunity to declining launch costs: "Manufacturing in space is one of the big new opportunities opening up as launch costs fall, and BioOrbit is an exciting British start-up well-placed to take advantage with extraordinary innovations in cancer immunotherapy." — Lord David Willetts, Chair, UK Space Agency, TechFundingNews, April 2026. Space Minister Liz Lloyd added government endorsement: "BioOrbit is a compelling example of world-leading UK innovation — harnessing the unique environment of space to make pharmaceutical-grade materials that could transform outcomes for cancer patients." — Space Minister Liz Lloyd, TechFundingNews, April 2026.

Source: TechFundingNews (April 2026); Business20Channel.tv analysis. *Items marked with an asterisk are based on publicly available information not confirmed in the source article and should be treated as indicative.

Business20Channel.tv Analysis

What the Capital Strategy Reveals

Our assessment is that BioOrbit's seed round is structured to achieve two distinct objectives. First, the £9.8 million provides approximately 18–24 months of operational runway to advance the BOX system from feasibility study to a prototype capable of orbital demonstration — a timeline that aligns with the broader commercial launch schedules of SpaceX rideshare missions and emerging European launch providers. Second, the investor syndicate is carefully constructed. LocalGlobe and Seedcamp provide credibility within the London deep-tech ecosystem. Breega extends the network into continental Europe. The involvement of healthcare-adjacent angels — though unnamed — suggests BioOrbit is already building relationships that could facilitate a Series A led by a specialist life sciences fund, likely in the £25–40 million range.

The Reformulation Thesis: Compelling but Unproven

The strongest element of BioOrbit's proposition is the specificity of its reformulation pathway. The company is not simply proposing to manufacture drugs in space for novelty; it is targeting a defined clinical problem — the inability to produce crystal structures suitable for subcutaneous delivery under terrestrial gravity conditions. If this thesis is validated, the commercial implications extend well beyond oncology. Rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease are all treated with monoclonal antibodies that currently require infusion. However, we must be candid about the risks. No in-space pharmaceutical manufacturing process has yet achieved GMP (Good Manufacturing Practice) certification. The regulatory pathway BioOrbit is pursuing with the MHRA is genuinely unprecedented — which means timelines are inherently unpredictable. Varda Space Industries, despite its operational lead, has not yet achieved commercial pharmaceutical production either, suggesting that the technical and regulatory hurdles are non-trivial for the entire sector.

The Astronaut Endorsement Factor

Major Tim Peake's endorsement, while not an investment, carries weight within the UK space ecosystem: "BioOrbit is turning bold imagination into real-world progress — and their record-breaking seed round demonstrates the real market potential of space manufacturing." — Major Tim Peake, British European Astronaut, TechFundingNews, April 2026. Peake's profile lends public credibility, but institutional investors will ultimately judge BioOrbit on data from orbital demonstration missions, not testimonials. The path from £9.8 million seed to a functioning orbital pharmaceutical supply chain is long and capital-intensive. Our estimate, based on comparable deep-tech hardware companies, is that BioOrbit will require £50–100 million in total funding before reaching commercial-scale production.

Why This Matters for Industry Stakeholders

For pharmaceutical executives, BioOrbit represents a potential new contract manufacturing modality. If orbital crystallisation can be industrialised, major pharma companies may partner with or acquire space-manufacturing startups rather than build capabilities in-house. The economics only work, however, if the value per kilogram of the output drug substantially exceeds the cost per kilogram of orbital launch — currently estimated at $2,700–4,000 per kg on a SpaceX Falcon 9 rideshare mission.

For healthcare policymakers, particularly within the NHS and NICE, the prospect of converting infusion-dependent cancer therapies to home-administered formulations is directly relevant to ongoing capacity planning. If BioOrbit's approach proves viable within 5–7 years, it should be factored into long-term oncology service models.

For investors in the European deep-tech ecosystem, this round signals that institutional VCs are willing to back hardware-intensive, pre-revenue space companies at meaningful valuations. The involvement of LocalGlobe and Breega at seed stage suggests a degree of conviction that was largely absent from European venture capital space-tech allocations even 18 months ago.

Forward Outlook

BioOrbit faces a multi-year execution challenge that will test both its technology and the patience of its investors. The immediate priorities are clear: advance BOX from feasibility study to orbital prototype, secure a demonstration mission slot — likely via a rideshare arrangement with SpaceX or Rocket Lab — and produce crystallisation data sufficient to progress the MHRA regulatory engagement from exploratory discussions to a formal application pathway. The broader question for the sector is whether in-space pharmaceutical manufacturing will follow the trajectory of commercial satellite broadband — where early scepticism gave way to operational reality within a decade — or whether it will join the long list of technically plausible but commercially unviable space ventures. Matthieu Vallin, Partner at Breega, expressed conviction: "We couldn't think of a better use of space than to advance cancer treatments, and Katie and Leonor are building a world-class team to make that a reality." — Matthieu Vallin, Partner, Breega, TechFundingNews, April 2026. The answer will depend not on ambition — of which there is no shortage — but on whether a microwave-sized box orbiting Earth at 28,000 km/h can consistently produce crystals that 40 years of ground-based pharmaceutical science could not.

Key Takeaways

• BioOrbit's £9.8 million seed round, announced 30 April 2026, is claimed as the largest ever for in-space manufacturing, though this has not been independently verified.
• The company's BOX unit targets a specific clinical bottleneck: producing crystal structures in microgravity that enable subcutaneous reformulation of infusion-dependent cancer drugs.
• Varda Space Industries holds an operational lead, having already returned drug crystals from orbit, but BioOrbit's focus on repeatable industrial-scale crystallisation may prove a distinct competitive position.
• The MHRA regulatory pathway BioOrbit is pursuing could establish global precedent for off-planet pharmaceutical manufacturing — a first-mover advantage with lasting strategic value.
• Investors should expect a 5–7 year timeline and £50–100 million in total capital requirements before commercial-scale production becomes feasible.

References & Bibliography

[1] TechFundingNews. (2026, April 30). BioOrbit bags £9.8M from LocalGlobe, Breega, Seedcamp and others in largest seed raise for in-space drug manufacturing. https://techfundingnews.com/bioorbit-bags-9-8m-from-localglobe-breega-seedcamp-and-others-in-largest-seed-raise-for-in-space-drug-manufacturing/

[2] LocalGlobe. (2026). Portfolio — BioOrbit. https://localglobe.vc/

[3] Breega. (2026). Investments. https://breega.com/

[4] Seedcamp. (2026). Portfolio. https://seedcamp.com/

[5] UK Space Agency. (2026). Programmes and funding. https://www.gov.uk/government/organisations/uk-space-agency

[6] Medicines and Healthcare Products Regulatory Agency. (2026). Innovation and regulatory guidance. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency

[7] Varda Space Industries. (2026). Company overview. https://www.varda.com/

[8] Space Forge. (2026). Company overview. https://www.spaceforge.co.uk/

[9] SpaceX. (2026). Falcon 9 rideshare programme. https://www.spacex.com/vehicles/falcon-9/

[10] Rocket Lab. (2026). Launch services. https://www.rocketlabusa.com/

[11] NASA. (2026). In-space manufacturing research. https://www.nasa.gov/

[12] European Medicines Agency. (2026). Regulatory framework. https://www.ema.europa.eu/en

[13] US Food and Drug Administration. (2026). Drug manufacturing guidance. https://www.fda.gov/

[14] National Health Service. (2026). Cancer services. https://www.nhs.uk/

[15] NICE. (2026). Technology appraisals. https://www.nice.org.uk/

[16] World Health Organization. (2026). GMP standards and specifications. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/gmp

[17] Redwire Corporation. (2026). In-space manufacturing. https://redwirespace.com/

[18] Business20Channel.tv. (2026). Space-Tech coverage. https://business20channel.tv/?category=Space-Tech

[19] Business20Channel.tv. (2026). Healthcare technology coverage. https://business20channel.tv/?category=Healthcare

[20] Business20Channel.tv. (2026). Deep-Tech sector analysis. https://business20channel.tv/?category=Deep-Tech

[21] Business20Channel.tv. (2026). Venture Capital coverage. https://business20channel.tv/?category=Venture-Capital